Danielle Aparecida Ferreira de Oliveira Marrafon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Danielle Aparecida Ferreira de Oliveira Marrafon has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Tiago Marques dos Reis
Universidade Federal de Alfenas
5 shared publications - Larissa Helena Torres
Department of Food and Drugs, Faculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, MG, Brazil
4 shared publications - Márcia Helena Miranda Cardoso Podestá
Universidade Federal de Alfenas
3 shared publications - Carla Speroni Ceron
Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, Brazil
2 shared publications - Carlos Marcelo de Barros
Department of Medicine, Federal University of Alfenas (UNIFAL-MG), Rua Gabriel Monteiro da Silva, 700, Centro, Alfenas 37133-840, Minas Gerais, Brazil
2 shared publications - Milena Carla Espósito
Department of Food and Drugs, School of Pharmaceutical Sciences Federal University of Alfenas Alfenas Brazil
2 shared publications
Latest Publications
- 28 January 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (6) , 6561-6577
Effectiveness and safety of the use of sodium nitrite in patients with hypertension and pulmonary hypertension: a scoping review
Evidence suggests that sodium nitrite may be effective in the treatment of hypertension and pulmonary hypertension. However, its use remains debated due to safety concerns. In response, a scoping review was conducted to map current knowledge on the efficacy and safety of sodium nitrite in patients with hypertension or pulmonary hypertension, addressing the question: What evidence supports the effectiveness and safety of using sodium nitrite in these patients? The databases MEDLINE (PubMed), EMBASE, Scopus, Web of Science, and LILACS were searched for clinical studies on hypertensive patients at any disease stage without restrictions on age, sex, ethnicity, publication date, or status. The primary outcomes analyzed were the efficacy and safety of sodium nitrite. A total of nine articles were included, eight from databases and one from gray literature. Sample sizes ranged from 5 to 36 patients, with sodium nitrite doses between 240 µg/kg/h and 325 mg. Five studies showed positive results for treating essential hypertension. Regarding safety, only one study raised concerns about adverse effects, probably due to the high dose that was used. In pulmonary hypertension patients classified as groups 2, 3, and 5, four studies suggested sodium nitrite was effective and safe, but it was ineffective in group 1. The studies included several significant limitations that should be considered. As such, the current evidence is insufficient to definitively confirm the efficacy and safety of sodium nitrite in hypertensive patients. Further research with larger sample sizes is necessary to obtain more conclusive results.
- 28 January 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (6) , 6561-6577
Effectiveness and safety of the use of sodium nitrite in patients with hypertension and pulmonary hypertension: a scoping review
Evidence suggests that sodium nitrite may be effective in the treatment of hypertension and pulmonary hypertension. However, its use remains debated due to safety concerns. In response, a scoping review was conducted to map current knowledge on the efficacy and safety of sodium nitrite in patients with hypertension or pulmonary hypertension, addressing the question: What evidence supports the effectiveness and safety of using sodium nitrite in these patients? The databases MEDLINE (PubMed), EMBASE, Scopus, Web of Science, and LILACS were searched for clinical studies on hypertensive patients at any disease stage without restrictions on age, sex, ethnicity, publication date, or status. The primary outcomes analyzed were the efficacy and safety of sodium nitrite. A total of nine articles were included, eight from databases and one from gray literature. Sample sizes ranged from 5 to 36 patients, with sodium nitrite doses between 240 µg/kg/h and 325 mg. Five studies showed positive results for treating essential hypertension. Regarding safety, only one study raised concerns about adverse effects, probably due to the high dose that was used. In pulmonary hypertension patients classified as groups 2, 3, and 5, four studies suggested sodium nitrite was effective and safe, but it was ineffective in group 1. The studies included several significant limitations that should be considered. As such, the current evidence is insufficient to definitively confirm the efficacy and safety of sodium nitrite in hypertensive patients. Further research with larger sample sizes is necessary to obtain more conclusive results.
- 18 June 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (11) , 8515-8525
Safety of metamizole (dipyrone) for the treatment of mild to moderate pain—an overview of systematic reviews
Metamizole, as known as dipyrone or novaminsulfone is widely used, especially in Latin America, for its analgesic and antipyretic function. However, several countries have banned it due to the risk of agranulocytosis, skin necrosis, and other serious adverse effects. To assess the safety of metamizole compared to other commonly used non-opioid analgesics (paracetamol, ibuprofen, and acetylsalicylic acid). An overview of systematic reviews. The searches were performed in the PubMed, Cochrane Library, Embase, Scopus and LILACS databases. Systematic reviews of randomized and nonrandomized clinical trials with adult patients with mild to moderate pain that assessed the adverse effects of metamizole were included. A methodological quality assessment was performed through ROBIS. The protocol of this systematic review was submitted to the International Prospective Register of Systematic Reviews (Prospero, CRD42021295272). Of 387 identified studies, four were included, with a total of 20,643 participants, all submitted to a single dose by oral, intramuscular, or intravenous route. No study reported a serious adverse effect. However, 60 of 778 patients (7.7%) who used metamizole; 120/828 (14.5%) who used acetylsalicylic acid; 56/443 (12.6%) who used paracetamol; and 27/213 (12.7%) who used ibuprofen had mild adverse effects. A complementary statistical analysis showed that metamizole, at any dose, has a 38.8% lower chance of adverse effects compared to paracetamol and 46.8% compared to acetylsalicylic acid. The results shows that metamizole is a safe drug with evidence of a lower incidence of adverse effects compared to paracetamol and acetylsalicylic acid.
- 18 June 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (11) , 8515-8525
Safety of metamizole (dipyrone) for the treatment of mild to moderate pain—an overview of systematic reviews
Metamizole, as known as dipyrone or novaminsulfone is widely used, especially in Latin America, for its analgesic and antipyretic function. However, several countries have banned it due to the risk of agranulocytosis, skin necrosis, and other serious adverse effects. To assess the safety of metamizole compared to other commonly used non-opioid analgesics (paracetamol, ibuprofen, and acetylsalicylic acid). An overview of systematic reviews. The searches were performed in the PubMed, Cochrane Library, Embase, Scopus and LILACS databases. Systematic reviews of randomized and nonrandomized clinical trials with adult patients with mild to moderate pain that assessed the adverse effects of metamizole were included. A methodological quality assessment was performed through ROBIS. The protocol of this systematic review was submitted to the International Prospective Register of Systematic Reviews (Prospero, CRD42021295272). Of 387 identified studies, four were included, with a total of 20,643 participants, all submitted to a single dose by oral, intramuscular, or intravenous route. No study reported a serious adverse effect. However, 60 of 778 patients (7.7%) who used metamizole; 120/828 (14.5%) who used acetylsalicylic acid; 56/443 (12.6%) who used paracetamol; and 27/213 (12.7%) who used ibuprofen had mild adverse effects. A complementary statistical analysis showed that metamizole, at any dose, has a 38.8% lower chance of adverse effects compared to paracetamol and 46.8% compared to acetylsalicylic acid. The results shows that metamizole is a safe drug with evidence of a lower incidence of adverse effects compared to paracetamol and acetylsalicylic acid.
- Open Access
- 15 July 2023
- Published by IP Innovative Publication Pvt Ltd in Journal of Pharmaceutical and Biological Sciences
- Vol. 11 (1) , 18-25
Tapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review
Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.
- 15 July 2023
- Published by IP Innovative Publication Pvt Ltd in Journal of Pharmaceutical and Biological Sciences
- Vol. 11 (1) , 18-25
Open AccessTapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review
Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.
- 13 December 2022
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 50 (3) , 256-263
Oral pregabalin is effective as preemptive analgesia in abdominal hysterectomy—A randomized controlled trial
Postoperative pain is one of the main negative symptoms resulting from surgery and the use of new methods to control this symptom is of ever‐increasing relevance. Opioid‐sparing strategies, such as multimodal analgesia, are trends in this scenario. Pregabalin is a well‐established treatment for neuropathic pain; however, it is still controversial in the surgical context for postoperative analgesia. This study investigated the effect of pregabalin on postoperative analgesia in patients undergoing abdominal hysterectomy. It is a prospective, randomised, double‐blind, placebo‐controlled clinical trial. Female patients undergoing abdominal hysterectomy were randomised to use pregabalin (group P1), 300 mg orally 2 h before surgery, or identical placebo pills (group P0). The main outcome includes the postoperative pain index by visual analogue scale (VAS) and McGill's pain questionnaire. Secondary outcomes include opioid consumption and the presence of adverse effects. A value of p < 0.05 was used to reject type I error. Fifty‐five patients were randomised amongst the groups. Patients in group P1 had lower pain rates by VAS scale, both at rest and in active motion, than group P0. In McGill's questionnaire, patients from group P1 also had lower pain rates (12 × 28.5). There was approximately twice as much opioid consumption amongst patients in group P0. Regarding side effects, there was a difference between the two groups only for dizziness, being more incident in group P1. This study suggests that pregabalin is an important adjuvant drug in treating postoperative pain in patients with abdominal hysterectomy.
- 13 December 2022
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 50 (3) , 256-263
Oral pregabalin is effective as preemptive analgesia in abdominal hysterectomy—A randomized controlled trial
Postoperative pain is one of the main negative symptoms resulting from surgery and the use of new methods to control this symptom is of ever‐increasing relevance. Opioid‐sparing strategies, such as multimodal analgesia, are trends in this scenario. Pregabalin is a well‐established treatment for neuropathic pain; however, it is still controversial in the surgical context for postoperative analgesia. This study investigated the effect of pregabalin on postoperative analgesia in patients undergoing abdominal hysterectomy. It is a prospective, randomised, double‐blind, placebo‐controlled clinical trial. Female patients undergoing abdominal hysterectomy were randomised to use pregabalin (group P1), 300 mg orally 2 h before surgery, or identical placebo pills (group P0). The main outcome includes the postoperative pain index by visual analogue scale (VAS) and McGill's pain questionnaire. Secondary outcomes include opioid consumption and the presence of adverse effects. A value of p < 0.05 was used to reject type I error. Fifty‐five patients were randomised amongst the groups. Patients in group P1 had lower pain rates by VAS scale, both at rest and in active motion, than group P0. In McGill's questionnaire, patients from group P1 also had lower pain rates (12 × 28.5). There was approximately twice as much opioid consumption amongst patients in group P0. Regarding side effects, there was a difference between the two groups only for dizziness, being more incident in group P1. This study suggests that pregabalin is an important adjuvant drug in treating postoperative pain in patients with abdominal hysterectomy.
- Open Access
- 31 December 2020
- Published by Universidade Federal de Goias in Revista UFG
- Vol. 20
Enfrentamento à Covid-19: união de esforços para combater a disseminação do vírus
A pandemia do novo coronavírus surpreendeu todo mundo com seu início abrupto e capacidade de disseminação entre as pessoas. A lavagem das mãos é uma das medidas mais eficazes para prevenir o contágio pelo SARS-CoV-2, mas nem sempre é possível em função de demandar o uso de agua e sabão. Nesse contexto, uso do álcool etílico emerge como estratégia alternativa à higienização com água e sabão pela praticidade do uso e efetividade de ação contra o vírus. Considerando o importante papel das universidades na formação de novos profissionais, engajados com melhoria das condições sociais, e seu compromisso com a comunidade em situações de vulnerabilidade, este estudo tem por objetivo relatar a experiência da Farmácia Universitária da Universidade Federal de Alfenas no desenvolvimento de uma ação de Extensão para produção, fracionamento, envase e rotulagem de álcool etílico com fins de emprego nos serviços do Sistema Único de Saúde e demais órgãos públicos destinados ao atendimento da população.
- 31 December 2020
- Published by Universidade Federal de Goias in Revista UFG
- Vol. 20
Open AccessEnfrentamento à Covid-19: união de esforços para combater a disseminação do vírus
A pandemia do novo coronavírus surpreendeu todo mundo com seu início abrupto e capacidade de disseminação entre as pessoas. A lavagem das mãos é uma das medidas mais eficazes para prevenir o contágio pelo SARS-CoV-2, mas nem sempre é possível em função de demandar o uso de agua e sabão. Nesse contexto, uso do álcool etílico emerge como estratégia alternativa à higienização com água e sabão pela praticidade do uso e efetividade de ação contra o vírus. Considerando o importante papel das universidades na formação de novos profissionais, engajados com melhoria das condições sociais, e seu compromisso com a comunidade em situações de vulnerabilidade, este estudo tem por objetivo relatar a experiência da Farmácia Universitária da Universidade Federal de Alfenas no desenvolvimento de uma ação de Extensão para produção, fracionamento, envase e rotulagem de álcool etílico com fins de emprego nos serviços do Sistema Único de Saúde e demais órgãos públicos destinados ao atendimento da população.